|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,652,880: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 6,652,880?
U.S. Patent 6,652,880 pertains to a pharmaceutical composition containing a specific class of compounds used as inhibitors of the enzyme HCV NS3/4A protease, primarily aimed at treating hepatitis C virus (HCV) infection.
- Patent issuance: November 25, 2003.
- Assignee: Vertex Pharmaceuticals Incorporated.
- Application filing date: March 2, 2001.
Scope focuses on compounds, methods of their use, and pharmaceutical formulations for HCV inhibition.
Key patent categories covered:
- Chemical compounds: Small-molecule inhibitors with defined structural motifs targeting HCV NS3/4A.
- Methods of use: Administration methods for treating HCV infection, including dosing regimens.
- Pharmaceutical compositions: Formulations for clinical and commercial development.
- Prodrug and salt forms: Variations intended to modulate bioavailability and stability.
What do the claims specify?
The patent contains 28 claims, divided mainly into composition claims (compound claims), method claims, and formulation claims.
Composition claims
- Cover specific chemical structures, notably inhibitors with a core backbone featuring various substituents.
- Claims specify certain R groups attached to the core scaffold, e.g., specific heterocycles, alkyl groups, or amino acid-like residues.
Method claims
- Encompass administering the compounds to treat HCV infection.
- Cover both prophylactic and therapeutic uses.
- Incorporate claims directed at dosing regimens, such as administering in combination with other antiviral agents.
Formulation claims
- Address pharmaceutical compositions, e.g., tablets, capsules, or injectable forms containing the claimed compounds.
- Include claims on carriers, excipients, and delivery methods.
Key points in claims analysis:
- The primary claims focus on the chemical structures with R groups limited to certain heteroatoms and side chains.
- Claims exclude compounds with certain undesirable groups to define novelty and inventive step.
- Use of Markush structures enables broad coverage over related compounds.
How does the patent fit into the patent landscape?
Prior art context
- Filed in 2001, during early development phases of HCV direct-acting antivirals.
- Related to early NS3/4A protease inhibitor research.
- Prior art includes compounds like boceprevir (cricDC, FDA 2011) and telaprevir (FDA 2011). But these came later.
Patent family and subsequent patents
- This patent forms part of a broader patent family covering Vertex’s protease inhibitors.
- Subsequent patents widen scope to include combinations, formulations, and new chemical entities based on the initial scaffold.
Competitive positioning
- Held broad claims covering multiple compound classes.
- Patents from competitors focus on different protease inhibitor scaffolds, e.g., Merck’s MK-7009, or GS-3535 (sofosbuvir).
- Patent expiration: 20 years from filing, expected around March 2021-2021+ (considering patent term adjustments).
Litigation and licensing
- No publicly available litigation linked specifically to this patent.
- Used as part of Vertex’s portfolio for licensing negotiations and partnering.
Patent expiration implications
- As the patent potentially expires, generic manufacturers could enter the market, reducing costs.
- Vertex's ongoing patent filings have aimed to extend protection via new formulations and combinations.
Summary of the patent landscape for HCV protease inhibitors
| Patent Type |
Focus Area |
Key Features |
Filing Date |
Expiry Date |
Status |
| Original compound patents |
Small molecules targeting NS3/4A |
Specific heterocyclic structures, R group modifications |
2001 |
2021+ |
Expired or nearing expiration |
| Composition patents |
Formulations |
Tablets, capsules, salts |
2002-2003 |
2022+ |
Active in several jurisdictions |
| Method patents |
Use of compounds |
Dosing methods, combination therapies |
2003 |
2023+ |
Varying statuses |
| Follow-on patents |
Improved compounds/formulations |
New scaffolds, prodrugs, delivery methods |
2004-2015 |
2024+ |
In force |
Key Takeaways
- U.S. Patent 6,652,880 claims broad chemical classes of NS3/4A protease inhibitors with therapeutic and pharmaceutical use.
- Its claims set a foundation for Vertex's antiviral portfolio and are part of a strategic patent family.
- The patent’s expiration around 2021 potentially opens the market for generics.
- The patent landscape was heavily focused on small-molecule inhibitors during the early 2000s, with ongoing innovation in formulation and combination therapies.
5 Frequently Asked Questions
1. What specific chemical classes are covered under the patent claims?
The patent covers heterocyclic small-molecule inhibitors with variable R groups attached to a core scaffold, aimed at inhibiting HCV NS3/4A protease.
2. How broad are the claims in terms of chemical diversity?
Claims encompass multiple Markush groups, allowing coverage over numerous related compounds, but exclude certain groups to maintain novelty.
3. Are there any active legal litigations involving this patent?
No known litigations directly target this patent; it has primarily been used in licensing and patent portfolio strategies.
4. When does the patent expire, and what does this imply for market competition?
Expected expiration around March 2021, after which generic competition likely increases, reducing treatment costs.
5. How has the patent landscape evolved since the original filing?
Vertex filed subsequent patents extending exclusivity through new analogs, formulations, and combination therapies, which may provide additional patent protection beyond 2021.
References
- U.S. Patent 6,652,880. (2003). Pharmaceutical compounds for HCV inhibition. U.S. Patent and Trademark Office.
- Kauffman, R., & Sablon, J. (2011). Hepatitis C virus protease inhibitors. Expert Opinion on Therapeutic Patents, 21(8), 1079–1089.
- HCV Antiviral Drugs Market Analysis. (2020). GlobalData.
More… ↓
⤷ Start Trial
|
